Abstract
Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.
| Original language | English |
|---|---|
| Pages (from-to) | 256-260 |
| Number of pages | 5 |
| Journal | Current Opinion in Rheumatology |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2006 |
Fingerprint
Keywords
- Disease-modifying osteoarthritis drugs
- Doxycycline
- Glucosamine
- Hyaluronic acid
- Osteoarthritis
ASJC Scopus subject areas
- Rheumatology
- Immunology
Cite this
An update on osteoarthritis therapeutics. / Hogenmiller, M. Scott; Lozada, Carlos.
In: Current Opinion in Rheumatology, Vol. 18, No. 3, 01.05.2006, p. 256-260.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An update on osteoarthritis therapeutics
AU - Hogenmiller, M. Scott
AU - Lozada, Carlos
PY - 2006/5/1
Y1 - 2006/5/1
N2 - Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.
AB - Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.
KW - Disease-modifying osteoarthritis drugs
KW - Doxycycline
KW - Glucosamine
KW - Hyaluronic acid
KW - Osteoarthritis
UR - http://www.scopus.com/inward/record.url?scp=33646679608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646679608&partnerID=8YFLogxK
U2 - 10.1097/01.bor.0000218945.96988.0a
DO - 10.1097/01.bor.0000218945.96988.0a
M3 - Article
VL - 18
SP - 256
EP - 260
JO - Current Opinion in Rheumatology
JF - Current Opinion in Rheumatology
SN - 1040-8711
IS - 3
ER -